Daniel Vasella
Co-founder 1996Background
Daniel Vasella served as the first CEO of the merged Novartis entity from 1996 to 2002, executing the complex integration of Ciba-Geigy and Sandoz. His defining moment was the decision to cut 10,000 jobs and close redundant R&D sites in 1997, a brutal but necessary move to achieve the cost synergies required to survive the pharmaceutical consolidation wave of the late 1990s. This decision established the company's long-term philosophy of prioritizing scientific focus and operational efficiency over legacy employment commitments.
Role at Novartis AG
Novartis possesses arguably the most historic, entrenched founding story in the entire global pharmaceutical industry, representing the 1996 mega-merger of two ancient, competitive Swiss chemical dynasties whose origins date back to the 18th-century dye industry in Basel. The modern corporate entity was created in 1996 through the historic, shocking $27 billion mega-merger of Ciba-Geigy and Sandoz (which, at the time, was the largest corporate merger in global history). The deepest foundational roots trace back to 1758, when Johann Rudolf Geigy-Gemuseus began trading specialized chemicals and dyes in Basel, Switzerland (forming Geigy). A century later, in 1859, a brilliant chemist named Alexander Clavel established a factory in Basel to manufacture advanced synthetic fuchsine dye (forming Ciba). In 1970, these two local rivals merged to form the Ciba-Geigy conglomerate. The other pillar, Sandoz, was founded in 1886 by Dr. Alfred Kern and Edouard Sandoz, also in Basel. Like their rivals, they started by heavily manufacturing complex synthetic dyes for the textile industry. However, the world-changing pivot for all these Swiss dye companies occurred in the late 19th and early 20th centuries. They discovered a 'eureka' moment: the complex organic chemistry required to synthesize vibrant fabric dyes was identical to the complex chemistry required to synthesize effective pharmaceutical drugs. By executing the 1996 merger, the newly formed Novartis (derived from the Latin 'novae artes,' meaning new skills) consolidated centuries of intertwined, secretive Swiss chemical expertise, establishing the dominant bedrock of the modern global pharmaceutical industry.